Navigation Links
Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR

clinical and clinical development of PX-866; the therapeutic and commercial potential of PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof; and future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes", "anticipates", "plans", "expects", "will", "intends", "potential", "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the clinical development of PX-866; the therapeutic and commercial potential of PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof, and future clinical development plans. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACT: Investor and Media Relations Contact: Stephanie Seiler, Ph.D.,Gemini BioProjects LLC, (206) 713-0124, ir@biomira.com

Ticker Symbol: (Toronto:BRA.),(NASDAQ-NMS:BIOM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... Aug. 22, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, is pleased to ... medical cannabis conference taking place at the Faculty ... , on October 22, 2014.  The multilingual conference ... as researchers, health professionals, and patients, to discuss ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... Results Reported at American Association for Dental Research ... Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated ... body,s mucosal,defenses, today announced preliminary results from a ... channel blocker, P-552-02, as a topical,therapy for dry ...
... April 7 A biosimilar product for,treating the ... the,white blood cells of patients is safe and ... a reference,product. This is the result of a ... company Kwizda Pharma GmbH and the Indian manufacturer,INTAS ...
Cached Medicine Technology:Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 2Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Athens, GA (PRWEB) August 23, 2014 Young adults ... drinking or doing drugs should pick up the phone and call ... troubled teen drug addict . , Troubled Teen Athens ... who is ready to finally take the necessary steps to end ... help, they are quick to go to friends or peers when ...
(Date:8/23/2014)... Wilmington, NC (PRWEB) August 23, 2014 ... across North Carolina. It’s no different in Wilmington, NC. ... Young adults are falling victim to drug and alcohol ... young people are looking to overcome substance abuse, but ... Finding an adolescent treatment facility can be a challenge ...
(Date:8/22/2014)... 23, 2014 Search Engine Optimization ... first page of search engines and get more ... has recently compared many Linux hosting suppliers and ... are the most recommended Linux hosting suppliers for ... Europe to buy high quality Linux hosting (including ...
(Date:8/22/2014)... On Friday, Aug. 22, Liberty University unveiled ... , hosting a ceremony in its courtyard attended by ... public welfare. , The 162-member inaugural class of the ... joined Liberty staff, faculty, and community leaders in celebrating ... medical school. Classes began on Monday, Aug. 4. , ...
Breaking Medicine News(10 mins):Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4
... Allscripts-Misys Healthcare,Solutions, Inc. (formerly named Allscripts Healthcare ... Delaware ("Allscripts") and,headquartered in Chicago, Illinois, announced today ... all of its 3.50% Convertible Senior Debentures,due 2024 ... 100% of the principal,amount of the Debentures being ...
... Watch and Jim Shank attribute the change to public outrage ... , WASHINGTON, Dec. 10 Wal-Mart Watch claimed ... a subrogation exception to the company,s 2009 health care plan ... Debbie Shank. , , ...
... ON. For the first time ever, an international ... the world,s tallest mountain, shedding some light on what ... on earth. , The team,s surprising findings shatter commonly-held ... falling ice and pulmonary oedema (lung problems) and highlight ...
... T ),has announced a contribution of A$38,000 ... support disadvantaged children in Australia. This is,the fifth ... Founded,in 1922, The Smith Family is a national, independent ... a better future,through education. , ...
... the United Kingdom and hires Michael Dyson to run European operations. ... ... -- DNA2.0, the leading gene synthesis and protein engineering company, today ... of the United Kingdom-based DNA2.0 Ltd. Michael Dyson, PhD, has been ...
... (duloxetine HCl) 60 mg to 120 mg once daily ... patients who had previously responded to the,medication and who ... patients who experienced at least three depressive episodes in ... Results from the 52-,week maintenance phase of the ...
Cached Medicine News:Health News:Allscripts Announces Expiration of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 2Health News:Wal-Mart's 2009 Health Care Plan Includes 'Debbie Shank Exception' 2Health News:Wal-Mart's 2009 Health Care Plan Includes 'Debbie Shank Exception' 3Health News:Team probes why climbers die on Mount Everest 2Health News:AT&T Supports the Smith Family's Learning For Life Program 2Health News:AT&T Supports the Smith Family's Learning For Life Program 3Health News:AT&T Supports the Smith Family's Learning For Life Program 4Health News:DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations 2Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 2Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 3Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 4Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 5Health News:Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R) 6
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
Rapid test for the presumptive identification of Candida albicans from culture media....
... is a system built ... and an imaging device ... zone size around an ... built-in expertise for detection ...
The best value and features offered in a complete EMR and Practice Management Solution...
Medicine Products: